Abstract:Abstract Introduction: Despite recent advances in targeted and immune-based therapies, the poor prognosis of lung adenocarcinoma (LUAD) with bone metastasis (BM) remains a challenge. Here, we aimed to investigate the potential biomarker for LUAD with BM. Methods: First, we collected 5 patients with traumatic amputation, 5 patients with bone infiltration, 9 LUAD patients who underwent curative resection or thoracoscopic lobectomy and 32 LUAD patients with BM who underwent bone biopsy in the Shanghai Sixth People's Hospital (China) from May 2014 to January 2017. 28 bone biopsy samples and 9 LUAD samples were used for immunohistochemistry assays (IHC) and OS (follow-up period of more than one year). Secondly, RT-PCR, IHC, and Western blotting (WB) were used to assess Aldehyde Dehydrogenase 2 (ALDH2) RNA and protein expression levels in samples of LUAD with BM. The Cancer Genome Atlas (TCGA) and Kaplan Meier plotter (KM Plotter) were used to generate survival curves. Thirdly, we analyzed the methylation associated genes and found DNA Methyltransferase 1 (DNMT1) and methyl-CpG binding domain 4 (MBD4) down-regulated the expression of ALDH2. Fourthly, we explored the impact of ALDH2 on tumor cell function and apoptosis via cell counting kit-8 (CCK8), Transwell and Fluorescence activated cell sorter (FACS). Then, we demonstrated that ALDH2 might affect mitogen-activated protein kinase (MAPK) and Epithelial-mesenchymal transition (EMT) markers through WB assays. Last, to confirm ALDH2 effect in vivo, we injected PLVX-flag-aldh2 and PLVX-flag H1299 cells into the left cardiac ventricle to check the effect of ALDH2 in BM and calculated the overall survival of mice. Results: We identified both mRNA and protein levels of ALDH2 were much lower in tumor tissues than in normal tissues, and they were even lower in tissues that exhibited increased migratory capacity. This low expression feature may be attributed to DNA methylation of ALDH2.The result of over expressing or knocking down ALDH2 showed that this gene inhibited proliferation, migration and promoted apoptosis both in vivo and in vitro. Overexpression of ALDH2 can inhibit MAPK signaling pathway and EMT in H1299. It also inhibited the occurrence of BM in LUAD and expanded survival in mice (p=0.003). Conclusions: This is the first time that instance where ALDH2 was associated with disease severity and progression in LUAD patients with BM. Thus, with this study, we have identified potential biomarkers and therapeutic targets for this disease. Supported by the National Natural Science Foundation of China (grant No. 81672852,81602519), a three year action plan to promote clinical skills and clinical innovation in municipal hospitals (20164Y0099), Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support (20172024). Citation Format: Mengdi Yang, Guangyu Yao, Zhiyu Wang, Jing Sun, Yiyi Zhou, Yifeng Gu, Hui Zhao. The differential expression of ALDH2 is correlated with prognosis of lungadenocarcinoma with bone metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-319.

Increased Expression of Acetaldehyde Dehydrogenase in Cisplatin-Resistant Human Lung Adenocarcinoma A549/DDP Cells

LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma

The Role of ADCY1 in Regulating the Sensitivity of Platinum-Based Chemotherapy in NSCLC

Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways

Aldehyde Dehydrogenases and Cancer Stem Cells.

Exploring the Role and Pathophysiological Significance of Aldehyde Dehydrogenase 1B1 (ALDH1B1) in Human Lung Adenocarcinoma

Aldehyde Dehydrogenase 3A1 is Robustly Upregulated in Gastric Cancer Stem-Like Cells and Associated with Tumorigenesis.

Abstract LB-319: the Differential Expression of ALDH2 is Correlated with Prognosis of Lungadenocarcinoma with Bone Metastasis

Integrated Analysis of DNA Methylation and Mrna Expression Profiling Reveals Candidate Genes Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer.

ALDH2 Repression Promotes Lung Tumor Progression via Accumulated Acetaldehyde and DNA Damage

Cisplatin-resistant Cells in Malignant Pleural Mesothelioma Cell Lines Show ALDH(high)CD44(+) Phenotype and Sphere-Forming Capacity.

Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells

UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells

Targeting ALDH2 to augment platinum-based chemosensitivity through ferroptosis in lung adenocarcinoma

Depleting DDX1 sensitizes non-small cell lung cancer cells to chemotherapy by attenuating cancer stem cell traits

Aldehyde dehydrogenase 2*2 knock-in mice show increased reactive oxygen species production in response to cisplatin treatment

Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)

Exogenous Glutathione Contributes to Cisplatin Resistance in Lung Cancer A549 Cells.

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-complementing Gene 1 in Lung Cancer Cell A549/DDP

Methylation-Induced Silencing of ALDH2 Facilitates Lung Adenocarcinoma Bone Metastasis by Activating the MAPK Pathway

ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients